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Background: We hypothesize that premenopausal endogenous estradiol may be associated 
with age at menarche and adult overweight and obesity, potentially contributing to breast 
cancer risk. 
Methods: We assessed age at menarche by questionnaire among 204 healthy Norwegian 
women, aged 25–35 years. Measures of body composition included body mass index (BMI 
kg/m
2), waist circumference (WC cm), waist to hip ratio (WHR) and fat percentage (DEXA). 
Daily salivary 17 -estradiol (E2) concentrations were collected throughout one entire 
menstrual cycle and assessed by radioimmunoassay (RIA). Linear regression analyses and 
linear mixed models for repeated measures were used and potential confounding factors and 
effect modifiers were tested. 
Results: Among women with an early age at menarche ( 12 years), the overall mean salivary 
E2 concentration increased by 3.7 pmol/L (95% confidence interval, 1.8-5.7) with each 9.8 cm 
(1 SD) increase in WC, which represents a 20.7 % change in the mean for the total group. 
Among the same early maturers, a 1 SD (0.06) change in WHR was directly associated with a 
24.0 % change in mean E2 concentration for the total group. Conclusion: Our findings support the hypothesis that early age at menarche, together with 
adult overweight and obesity, result in high levels of 17- -estradiol throughout the menstrual 
cycle. However, we have measurements only from one menstrual cycle.  
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Introduction 
The increasing breast cancer incidence worldwide follows trends toward earlier age at 
menarche (Onland-Moret et al., 2005), higher rates of obesity (IARC Handbook of Cancer 
Prevention, 2002;Ballard-Barbash et al., 2006) and  unfavourable metabolic profiles (visceral 
obesity,
 glucose intolerance, hypertension and dyslipidemia). Age at menarche (Key et al., 
2001;Clavel-Chapelon and Gerber, 2002;Butler et al., 2000;Kelsey et al., 1993) and obesity 
(IARC Handbook of Cancer Prevention, 2002;Ballard-Barbash et al., 2006) have been 
identified as risk factors for breast cancer. For each 1-year delay in menarche, the risk of 
breast cancer decreases by around 5%, and this menarcheal effect may be stronger in 
premenopausal than in postmenopausal women (Key et al., 2001), indicating a time-
dependent effect. Excessive body weight is associated with an increased risk of 
postmenopausal breast cancer, but has most often been observed to decrease the risk of 
premenopausal breast cancer (IARC Handbook of Cancer Prevention, 2002).  
A younger age at menarche is associated with higher cumulative exposure to ovarian 
hormones which may play a critical role in breast carcinogenesis (Pike et al., 1993;Bernstein, 
2002). Estrogens are considered to stimulate ductal growth and cell proliferation of breast 
epithelial cells. High levels of serum estrogens are associated with an increased risk of breast 
cancer among postmenopausal women (Key et al., 2002), but the role of estrogens in the 
etiology of premenopausal breast cancer are more complex (Sturgeon et al., 2004;Eliassen et 
al., 2006;Key et al., 2002) and is more difficult to study because of the complexity of 
measuring the cyclic variation of estrogens (Bernstein, 2002;Kaaks et al., 2005).  
Adiposity appears to be both a cause and a consequence of early age at menarche 
(Brown et al., 1996). Studies indicate that factors influencing energy balance and metabolism, 
such as physical activity and body composition, are strong predictors of age at menarche 
(Kirchengast et al., 1998;Chavarro et al., 2005). The improvement in living conditions,  
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nutrition and increase in energy intake, combined with a reduction in energy expenditure, may 
explain why age at menarche has dropped in Norway from about 16 years for women born 
around 1830, to 13 years for those born around 1960 (Rosenberg, 1991) and 1985 (Lien et al., 
2006). Importantly, several studies indicate that early maturation seems to increase overall 
adult fatness (Kirchengast et al., 1998;Key et al., 2001). 
  Little is known about the association between adult levels of estradiol throughout an 
entire menstrual cycle and age at menarche and adult body composition. We have previously 
observed that an unfavorable metabolic profile, including being overweight (Furberg et al., 
2005) and physically inactive (Jasienska et al., 2006), is associated with increased levels of 
free E2 throughout a menstrual cycle. In addition, we have previously observed  that 
unfavorable metabolic profile reflected by high energy intake and weight gain, together with 
physical inactivity, increases the risk of postmenopausal breast cancer (Thune et al., 
1997;Jasienska and Thune, 2001;Thune et al., 1998;Furberg et al., 2004). 
Thus, the aims of the present study were to elucidate the association between age at 
menarche and premenopausal 17- -estradiol levels throughout a menstrual cycle, and whether 
an unfavorable energy balance as expressed through a higher fat mass in adulthood might 
influence such an association.  
 
Materials and Methods 
Participants and study design 
A total of 204 women, aged 25–35 years were invited to participate in the Norwegian EBBA 
study during 2000–2002. Women who met the following criteria were included: self-reported 
regular menstruation (normal cycle length: 22–38 days within the previous 3 months), no use 
of steroid contraceptives and no pregnancy or lactation over the previous 6 months, no history 
of gynecological disorder and no chronic disorders (e.g. diabetes, hypo-/hyperthyroidism).  
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Participants were subsequently enrolled into the study and came to the Department of Clinical 
Research, University Hospital North Norway (UNN), at a scheduled time (Furberg et al., 
2005).  
All the participating women signed an informed consent form. The study was 
approved by the Regional Committee for Medical Research Ethics and the Norwegian Data 
Inspectorate. 
 
Questionnaires 
We used questionnaires (self and interviewer-administered by trained personal) to collect 
information on age at menarche, marital status, education, ethnicity, reproductive history, 
lifetime total physical activity, previous use of hormonal contraceptives, family history of 
cancer, smoking [“current smoker” (yes/ no), “how many cigarettes per day”] and alcohol 
[“do you drink alcohol” (yes/ no), “units of alcohol”]. In this questionnaire, all of the 
participants in particular answered questions about age at menarche at home, and then they 
went through the questions administrated by trained personal. Recall and a memory-probing 
aid that included a lifetime calendar were used. 
The validity of the response to the questions on smoking and alcohol has previously 
been studied (same age group, both men and women) by measurements of serum thiocynate 
concentrations (Knutsen and Knutsen, 1991) and levels of serum  -glutamyltransferans levels 
(Nilssen and Forde, 1991) respectively.  We collected dietary data on seven different days 
during the menstrual cycle (days 3–6 and 21–23) by a pre-coded food diary (Lillegaard et al., 
2005).  
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Clinical parameters  
Study participants met fasting on three subsequent visits during the collection period: first 
visit (days 1–5 of the menstrual cycle), second visit (days 7–12) and third visit (days 22–25) 
at the Department of Clinical Research, UNN, Tromsø. For the first visit, the participants met 
on the first day possible after onset of menstrual bleeding. Anthropometric measurements 
were taken with participants wearing light clothing and no footwear: height was measured to 
the nearest half-centimeter and weight to the nearest 0.1 kilogram on an electronic scale. 
Body mass index (BMI) was used to estimate relative weight. Waist circumference (WC) was 
measured in a horizontal line 2.5 cm above the umbilicus; hip circumference was measured at 
the largest circumference, both measured to the nearest 0.5 cm. Waist to hip ratio (WHR) was 
estimated. The participants underwent whole-body scan (days 7-12) using dual energy X-ray 
absorptiometry (DEXA – DPX-L 2288, Lunar Radiation Corporation, Madison, WI, USA), 
and the percentages of total and truncal fat tissue were estimated using standard Lunar 
software. In this study we have presented analysis using total tissue fat. Using truncal fat gave 
similar results.   
 
Serum samples 
Fasting serum blood samples were drawn from an antecubital vein in the morning on each of 
the three visits during the menstrual cycle. The blood was centrifuged and the serum 
separated. Serum concentrations of 17- -estradiol were measured in fresh sera at the 
Department of Clinical Chemistry, UNN (Furberg et al., 2005).  
 
Hormone analysis 
Women collected samples of their own saliva to plastic tubes pretreated with sodium azide at  
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home once a day, preferentially in the morning, for one entire menstrual cycle (Furberg et al., 
2005). They started on the first day of bleeding, according to previously established collection 
protocols developed at the Reproductive Ecology Laboratory at Harvard University, USA 
(Lipson and Ellison, 1996). 
17- -estradiol concentrations were measured in daily saliva samples using an 
125I-
based radioimmunoassay (RIA) kit (#39100, Diagnostic Systems Laboratory, Webster, TX, 
USA), along with published modifications to the manufacturer’s protocol (Furberg et al., 
2005). All samples were run in duplicate. All of a woman’s samples were run in the same 
batch, with women randomly assigned to batches. CV´s were calculated from high to low 
value pools (appropriate to the range of each steroid) that were run with each batch (Furberg 
et al., 2005). 
The sensitivity of the E2 assay (the lowest concentration of E2 distinguishable from 0 
at the 95% level) was 4 pmol/L.  Average intra-assay variability (estimated from the 50% 
binding point of the standard curve) was 9%, and the inter-assay variability ranged from 23% 
for lower values (15 pmol/L) to 13% for higher values (50 pmol/L). Salivary assays do have 
higher variability than serum assays because they are measuring levels that are one to two 
orders of magnitude lower in concentration. This may impact the results so the lower values 
(in the tale of the cycle) will have greater variability. 
Before statistical analysis, all cycles were aligned to the day of ovulation following 
published methods (Lipson and Ellison, 1996), based on the identification of the E2 drop at 
the mid-cycle (day 0), which provides a reasonable estimate of the day of ovulation. The 
values for 20 consecutive days for E2 (day -10 to + 9) from each cycle, aligned on day 0, were 
used in data analyses. Satisfactory identification of the mid-cycle E2 drop could not be made 
for 14 women and their cycles were not aligned.  In detail to study the total variation in 
estradiol concentration throughout a menstrual cycle and as anovulatory cycles are associated  
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with low estradiol exposure, all cycles, both anovalatory and ovulatory cycles, were included 
in this study.  
Overall mean salivary E2 concentration was calculated for all 204 women, while 
additional indices (i.e. follicular value) were calculated for the 190 women with aligned 
cycles. A mean follicular value was calculated by averaging E2 values for days -7 to -1. A 
mean luteal value was calculated by averaging the E2 values for cycle days 0 to + 11.  
 
Statistical analysis 
The study population was divided into three subgroups of age at menarche:   12 years, 12–14 
years and   14 years, based on the variation in age at menarche in a general western 
population. The various groups of age at menarche were then compared with regard to 
selected characteristics of the study population. We used one-way analysis of variance for 
continuous variables and  
2 tests for categorical variables. 
Age- and multivariate adjusted linear regression analyses were used to study the 
associations between mean salivary E2 concentration (overall, follicular and luteal phases of 
the menstrual cycle), age at menarche and different measures of body composition. Possible 
interactions were studied. 
In order to study whether variation in adult excess weight and fat distribution modified 
the association between age at menarche and salivary E2 concentrations, the body composition 
variables were dichotomized at the 75th percentile (75 percentile BMI:   26.5 kg/m
2, 75 
percentile DEXA total fat: 40 %, 75 percentile WC:   84 cm and 75 percentile WHR:   0.80), 
and age at menarche was categorized as   12 years and > 12 years. Additionally, the groups 
of women in these upper quartiles of BMI, DEXA total fat, WC and WHR were defined as 
being overweight, and/or obese (NIH and WHO definition; overweight: BMI   25.0 kg/m
2, 
obese: BMI  30.0 kg/m
2).   
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  We used a linear mixed model for repeated measures to study salivary E2 
concentrations throughout the entire menstrual cycle in relation to age at menarche and body 
composition. Different co-variance structures were explored and the results using 
heterogeneous Toeplitz are presented. Dunnett’s method was used for multiple comparisons. 
  Age adjusted and multivariate adjusted results are presented. Based on biological 
plausibility and common knowledge possible covariates such as age, birth weight, energy 
intake, smoking, alcohol, previous use of hormonal contraceptives, time to establishment of 
regular cycles, age at first birth, number of children and physical activity were tested in the 
model. The following variables contributed and were included in the final model; age, birth 
weight, smoking, physical activity. As none of the multivariate analyses gave different results 
compared to age adjusted analyses, we present figure 1 only with age adjusted results. 
  Collinearity was of no concern as Pearson’s correlation coefficient was   0.2 for all 
pairs of independent variables in the models. E2 measurements at the beginning and the end of 
the cycles are encumbered with higher coefficient of variation; therefore we included E2 
measurements from cycle day -10 to +9. SAS statistical package version 9.1. was used.  
 
Results 
The participating 204 healthy women were, on average, aged 30.7 years (24.9-35.9 
years) and reported a mean age at menarche of 13.1 years (9.2-19.5 years). The mean BMI 
was 24.4 kg/m
2 (16.9-39.8 kg/m
2), WC 79.5 cm (61.0-116.0 cm) and percentage fat 34.2% 
(16.7-52.1%) (Table II). Mean salivary E2 concentration was 17.9 pmol/L (not shown in 
table). Women with an age at menarche below 12 years were shorter (p = 0.03) and tended to 
have a higher BMI, a larger WC and a higher fat percentage than women with later age at 
menarche (>12–14 and   14 years) (Table I).   
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When studying estimated changes in overall mean salivary E2 concentrations for the 
total group, by changes (1 SD) in different body composition measures, we observed that an 
increase in any of these measures of body composition resulted in a multivariate adjusted 
increase in E2 concentration (Table II). For each 3.8 kg/m
2 (1 SD) increase in BMI, the 
overall mean age-adjusted level of E2 increased by 2.2 pmol/L (95% confidence interval, CI, 
1.0-3.4), which equals a 12.3% increase in mean overall concentration of E2 for the total 
group. For each 9.8 cm (1 SD) increase in WC, the overall mean concentration of E2 
increased by 1.6 pmol/L (95% CI, 0.4-2.8), which equals an 8.9% increase in mean overall 
concentration of E2 for the total group. Performing the same analyses but excluding the 14 
women who did not have a mid-cycle E2 drop, gave smaller estimated changes in salivary E2, 
but the conclusion did not change, 1 SD increase in the different body composition variables 
gave significant increase in E2 (data not shown). 
We observed no difference in estimated changes in E2 by different measures of body 
composition between the follicular and luteal phases of the menstrual cycle (Table II). 
In order to elucidate whether age at menarche influenced our results, stratified 
analyses by subgroups of age at menarche was performed (Table III). Women with early age 
at menarche ( 12 years) had an increase in overall mean E2 concentration by 3.7 pmol/L 
(95% CI, 1.8-5.7) by 9.8 cm (1SD) increase in WC (pinteraction=0.07); with each 0.06 (1 SD) 
increase in WHR, the overall mean E2 concentration increased by 4.3 pmol/L (95% CI, 2.0-
6.5) (pinteraction=0.03) and with each 7.6% (1SD) increase in total fat percentage, the overall 
mean E2 concentration increased by 2.9 pmol/L (95% CI, 0.2-5.5) (pinteraction=0.22). These 
results equal a change in mean overall concentration of E2 for the total group of 20.6%, 24.0% 
and 16.2%, respectively. Among women with age at menarche >12-14 years and  14 years, 
no significant associations were seen with adult body composition.   
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  To examine whether parity influenced our result, we performed analysis stratified by 
parity. Among women with early age at menarche ( 12 years), the relationship between 
measures of body fatness and overall E2 concentration was strongest in the subgroup of non-
parous women (data not shown). With each 0.06 (1 SD) increase in WHR, overall mean E2 
concentration increased by 6.1 pmol/L (95% CI, 1.5-10.9). However, no interaction between 
age at menarche, parity and the different anthropometric measurements were found and there 
were small numbers in each group.  
We examined the mean E2 concentrations by cycle day throughout the whole 
menstrual cycle in four groups stratified by age at menarche  12 years and >12 years and 
body fat and distribution measures at the 75% percentile (Fig. 1). Women characterized by 
both early age at menarche ( 12 years) and excess WC ( 84 cm, 75th percentile) or WHR 
( 0.80, 75th percentile) had age adjusted mean salivary E2 profiles that were higher 
throughout  the cycle, than the rest of the study population (Fig. 1). 
Using a linear mixed model for repeated measures, we examined how the mean E2 
concentration by cycle day in women with both early age at menarche and excess body 
weight (groups II, Fig. 1) differed from the concentrations in the other groups of women 
described. Figure1 is presented with age adjusted results, as none of the multivariate analyses 
gave different results compared to age adjusted analyses. 
The difference between women with age at menarche  12 and BMI  26.6 kg/m
2 
(group II, Fig. 1a) and the other groups of women described in Fig. 1a was significant for 
group I (p=0.04) and III (p=0.04), but not for group IV (p=0.43). There was no statistically 
significant interaction between the dichotomized menarche variable and the dichotomized 
variable of BMI (pinteraction=0.8). 
There were no significant differences between women with age at menarche  12 and 
DEXA % total fat   40% (group II, Fig. 1b) and the other groups of women described in Fig.  
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1b (groups II and I, p=0.17; groups II and III, p=0.15; groups II and IV, p=0.63). There was 
no statistically significant interaction between the dichotomized menarche variable and the 
dichotomized variable of DEXA % total fat (pinteraction=1.0).  
We examined how the mean E2 levels by cycle day throughout the whole cycle in 
women with both age at menarche  12 and WC  84 cm (group II, Fig. 1c) differed from the 
levels in each of the other groups of women described in Fig. 1c and observed significant 
differences for all comparisons (groups II and I, p=0.004; groups II and III, p=0.03; groups II 
and IV, p=0.01). There was a statistically significant interaction between the dichotomized 
menarche variable and the dichotomized variable of WC (pinteraction=0.02).  
Finally, the same pattern was observed in women with age at menarche  12 and WHR 
 0.8 (group II, Fig. 1d) and the other groups of women described in Fig. 1d (differences 
between group II in Fig. 1d and the other; group I, p=0.003; group III, p=0.04; group IV, 
p=0.007). There was a statistically significant interaction between the dichotomized menarche 
variable and the dichotomized variable of WHR (pinteraction<0.001).  
 
Discussion 
To our knowledge this is the first study to support the hypothesis that early age at menarche in 
combination with adult overweight and obesity, might result in an overall increase in 
concentrations of free, biologically active E2. We observed a clear pattern after adjustments 
for potential confounders of a 16-24% increase in E2 concentration among women reporting 
early age at menarche in combination with adult overweight and obesity.  
Several studies have suggested that lifestyle related factors, including metabolic 
profile, and reproductive factors as age at menarche, separately affect breast cancer risk by 
altering exposure to estrogens (Verkasalo et al., 2001;Jasienska and Thune, 2001;Bernstein, 
2002). Women with early age at menarche have been observed to have higher levels of serum  
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E2 throughout a cycle (Apter and Vihko, 1985;Apter and Vihko, 1983) and higher levels of 
urinary estrogen metabolites (Windham et al., 2002) than women with later age at menarche. 
Evidence is becoming more consistent that there is an inverse association between physical 
activity and estrogens (Irwin, 2006;Williams, 2003). 
Additionally, several studies have observed an association between early age at 
menarche and adult obesity (Laitinen et al., 2001;Kirchengast et al., 1998). It has been 
recognized that body fat is important for the initiation and maintenance of reproductive 
function in women, explaining why weight gain accelerates and energy restriction delays the 
onset of menses (Adair and Gordon-Larsen, 2001;Dunger et al., 2005) and early maturation 
may increase overall adult fatness (Kirchengast et al., 1998). In our study we also observed 
that women experiencing early maturation tended to also have an increased adult body fatness 
(p=0.07). 
The close relationship between obesity and age at menarche is supported in a recent 
intervention study, where age at menarche was delayed as a result of reduction in BMI and 
body fatness (Chavarro et al., 2005). Thus, an increase in E2 levels during late childhood and 
puberty may promote not only the onset of the first menstrual bleeding but also the 
development of higher amounts of body fat tissue. Moreover, body fat may acts as a 
secondary hormonal gland, influencing E2 levels during the whole of adult life (Kirchengast et 
al., 1998). Thus, our observation that subgroups of premenopausal women, characterized by 
both early age at menarche and adult overweight and obesity (high BMI, DEXA, WC and 
WHR), experience higher E2 levels throughout their menstrual cycle is biologically plausible. 
Furthermore, energy expenditure may reduce serum E2 levels (Bernstein et al., 1987;Kumar et 
al., 2005) and biologically active free E2 throughout a menstrual cycle (Jasienska et al., 
2006), supporting the hypothesis that excess weight may contribute to increased  estradiol 
levels among premenopausal women. Of importance, is also the observation that even among  
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our women, that were relatively thin, we observed an increase in the level of E2 with 
increasing relative body weight (BMI, WC, WHR, DEXA total fat). 
It should be noted that, by stratifying by parity, we observed the strongest 
interrelationship of age at menarche, BMI, WC and E2 levels observed throughout a menstrual 
cycle for non-parous women (data not shown). However, no significant interactions were 
found and due to small numbers in each group these results need to be interpretated with 
caution. Furthermore, in some studies parous women were observed to have higher 
premenopausal E2 levels than non-parous women (Bernstein, 2002;Kaaks et al., 2005) in 
contrast to others (Verkasalo et al., 2001), but  these studies have not been stratified by age at 
menarche. 
To our knowledge, no studies to date have examined if the subgroup characterized by 
early age at menarche and excessive body weight throughout premenopausal years are at high 
risk for breast cancer. Furthermore, our results may seem inconsistent with studies that have 
found a reduced risk of premenopausal breast cancer among women who were obese as young 
adults (IARC Handbook of Cancer Prevention, 2002;Ballard-Barbash et al., 2006;Ursin et al., 
1995). Nevertheless, several studies support our results indirectly; women with central obesity 
had increased risk of pre- and postmenopausal breast cancer (Wu et al., 2006), newly 
diagnosed cases of premenopausal breast cancer had significantly higher serum total E2 levels 
and higher WHRs than controls (Kumar et al., 2005) and women with follicular total and free 
E2 levels in the top 25% had a doubling of breast cancer risk (Eliassen et al., 2006). 
Furthermore, premenopausal overweight women who developed breast cancer had somewhat 
higher prediagnostic blood levels of E2 than those who did not develop breast cancer, which 
supports the importance of the levels of E2 among premenopausal women (Travis and Key, 
2003). However, many prior studies have not aligned estrogen assays to the same time during  
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the menstrual cycle making it difficult to compare results across studies (Kaaks et al., 
2005;Bernstein, 2002).  
Our observations of a higher E2 level among women who have both an early age at 
menarche and adult obesity support studies demonstrating a modest increase in breast cancer 
risk associated with younger age at menarche (Bernstein, 2002;Kelsey et al., 1993). To our 
knowledge these studies have not stratified by premenopausal body composition. The 
observed association between age at menarche and  breast cancer risk is often explained due 
to early establishment of regular cycles and longer time between age at menarche and first 
full-term pregnancy, and hence the overall higher total cumulative dose of estrogen 
throughout life. Furthermore, age at menarche is a good marker for determining total duration 
of endogenous estrogen exposure (Hagemans et al., 2004). Any factor that modifies menstrual 
cycle patterns and reduces the levels of E2 or the frequency of ovulation may reduce a 
woman’s lifetime risk of developing breast cancer (Bernstein et al., 1994). The observation 
that obesity in premenopausal women may lower this risk of breast cancer, has been 
hypothesized to be due to higher frequency of longer anovulatory cycles among obese women 
(IARC Handbook of Cancer Prevention, 2002;Ballard-Barbash et al., 2006). 
 Our study has several strengths, including daily saliva sampling for estimation of 
daily 17- -estradiol concentrations through an entire menstrual cycle. We used well-
developed and validated methods and assays to characterize the women’s exposure to free, 
biologically active E2 and performed comparisons of levels by aligned cycle days (Lipson and 
Ellison, 1996). This recommended approach, of examining all women at the same time during 
the menstrual cycle, is rarely achieved because of its logistic complexity (Kaaks et al., 
2005;Bernstein, 2002). Additionally, one trained nurse traced all the participants throughout 
the study, and all were met in the same clinical research department at a university hospital. 
This standardization enhanced the quality of our data and allowed us to sample all clinical  
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variables within the same narrow frame of the cycle for each participant, using uniform 
procedures. To limit any potential influence of season, women did not participate during 
months with no daylight (December and January).   
  In order to study if different anthropometric measurements in particular were 
associated with levels of E2, several measurements were included. Of notice, is the 
observation that even if DEXA % total fat is looked upon as a valid and objective fat 
measurement method, BMI, WC and WHR gave additional information. One explanation may 
be that our DEXA measurement does not allow an index of central obesity, as the truncal 
DEXA fat is measuring fat from the hips to the shoulders. Neither DEXA total fat or DEXA 
truncal fat, represent central adiposity in particular, in the same matter as WC and WHR. 
The present population is very homogenous which may strengthen the interpretation in 
smaller groups, but it also underlines the need for further studies among other ethnic groups. 
Additionally, in order to perform stratification by age at menarche and body composition, 
certain subgroups were small.  
Age at menarche was collected retrospectively and misclassification is possible, 
although several studies have found age at menarche to be recalled with high reliability (Must 
et al., 2002). In our study we used both interview and a life calendar to improve the accuracy 
of recall and age at menarche is in accordance with comparable observations in a large 
prospective study from Norway (Lien et al., 2006).  
 
Conclusion 
 
Reducing the lifetime levels of estrogen has been proposed as the most important step in 
lowering the risk of breast cancer in women. Our results suggest that women who experience 
early age at menarche and adult excess weight may experience higher levels of E2 throughout  
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a menstrual cycle. These findings underline the necessity to further study variation in 
biologically active estradiol by subgroups of women, in order to elucidate the associations 
between lifestyle factors, characteristics of women and breast cancer risk. 
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Figure legend: 
 
Figure 1. Age adjusted salivary 17-ß-estradiol concentrations by cycle day in women categorized by 
anthropometric measurements [Body mass index (BMI) (A), total tissue fat (DEXA) (B), waist circumference 
(WC) (C), and waist to hip ratio (WHR) (D)] and age at menarche over and below 12 years. Linear mixed 
models for repeated measurement.   
 , Group I: Menarche   12 years and anthropometric measurement under 75 percentile 
 , Group II: Menarche   12 years and anthropometric measurement over 75 percentile 
 , Group III: Menarche > 12 years and anthropometric measurement under 75 percentile  
 , Group IV: Menarche > 12 and anthropometric measurement over 75 percentile 
 
A Groups of BMI and age at menarche 
  Group I: Menarche   12 yrs and BMI < 26.5 kg/m
2, n= 34 
  Group II: Menarche   12 yrs and BMI   26.6 kg/m
2, n=15 
  Group III: Menarche > 12 yrs and BMI < 26.5 kg/m
2, n=119 
  Group IV: Menarche > 12 yrs and BMI   26.6 kg/m
2, n=36 
B Groups of DEXA and age at menarche 
  Group I: Menarche   12 yrs and DEXA < 40 %, n= 34 
  Group II: Menarche   12 yrs and DEXA   40 %, n=15 
  Group III: Menarche > 12 yrs and DEXA < 40 %, n=119 
  Group IV: Menarche > 12 yrs and DEXA   40 %, n=36 
C Groups of WC and age at menarche 
  Group I: Menarche   12 yrs and WC < 84 cm, n=32 
  Group II: Menarche   12 yrs and WC   84 cm, n= 17 
  Group III: Menarche > 12 yrs and WC < 84 cm, n=116 
  Group IV: Menarche > 12 yrs and WC   84 cm, n=39 
D Groups of WHR and age at menarche 
  Group I: Menarche   12 yrs and WHR < 0.8, n= 32 
  Group II: Menarche   12 yrs and WHR   0.8, n=17 
  Group III: Menarche > 12 yrs and WHR < 0.8, n=118 
  Group IV: Menarche > 12 yrs and WHR   0.8, n=37  
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Table I Characteristics of the study population: means, (SDs)* or proportions 
The Norwegian EBBA study (n = 204
†). 
 
 
Menarche 
  12 years 
(n = 49) 
Menarche 
> 12–14 years 
(n = 100) 
Menarche 
  14 years 
(n = 55) 
 
p value‡ 
Age, years  30.9 (2.8)  30.4 (2.9)  31.2 (3.5)  0.30 
Years of schooling  16.0 (3.1)  16.1 (3.0)  16.0 (3.1)  0.94 
Ethnic minority (Sami %)  12.2  6.0  7.3  0.41 
Body composition         
  Height (cm)  164.7 (5.3)  167.4 (7.0)  167.9 (6.3)  0.03 
  BMI (kg/m
2)  25.3 (4.7)  24.3 (3.2)  23.8 (3.7)  0.11 
  Waist circumference (WC) (cm)  81.1 (12.1)  79.9 (8.9)  77.5 (8.9)  0.15 
  Waist to hip ratio (WHR)  0.78 (0.07)  0.77 (0.06)  0.76 (0.06)  0.20 
  Total  tissue fat (%)  35.8 (7.8)  34.3 (7.5)  32.3 (7.4)  0.07 
Total cholesterol (mmol/L)  4.3 (0.7)  4.5 (0.8)  4.5 (0.7)  0.48 
HDL cholesterol (mmol/L)  1.5 (0.3)  1.6 (0.3)  1.6 (0.3)  0.35 
LDL/HDL ratio  1.8 (0.7)  1.8 (0.7)  1.7 (0.6)  0.85 
Saliva hormone concentrations (pmol/L)         
  Overall average 17ß estradiol  17.8 (9.3)  17.7 (8.7)  18.4 (8.5)  0.90 
Serum hormone concentration§ (nmol/L)         
  Serum estradiol   0.16 (0.07)  0.14 (0.06)  0.15 (0.06)  0.49 
 Menstrual and reproductive characteristics         
  Women with children (%)  49.0  47.0  49.1  0.96 
  Age at 1st birth(years)||  24.0 (2.8)  24.7 (3.8)  24.6 (4.7)  0.79 
  Cycle length (days)  28.1 (2.9)  28.1 (3.1)  28.6 (3.5)  0.63 
Previous use of hormonal contraceptives (%)  79.6  84.0  87.0  0.59 
Energy intake (kJ/day)  7895 (2033)  8197 (1897)  8079 (1801)  0.66 
Leisure time (MET h/week)  49.8 (34.6)  52.0 (33.7)  55.5 (41.5)  0.72 
Alcohol units per week among users (n = 190)  3.0 (4.0)  2.8 (3.1)  3.8 (3.5)  0.20 
Current smokers (%)  22.5  23.0  20.0  0.91 
 
*SDs = standard deviation. 
†Numbers may vary due to missing information. 
‡One way analysis of variance or  
2 test. 
§Blood sampling first visit (days 1–5). 
||For those who have children: n = 98, in each group: 24–47–27.  
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Table II Estimated changes* in salivary 17- -estradiol concentration (pmol/L) by 1 standard deviation (SD) 
increase in explanatory variables in total menstrual cycle (n=204)
 †, follicular and luteal phase (n =190)
†  
 
     
Mean E2 change (n=204) 
 
Mean E2 change-follicular index 
(n=190)
 § 
 
 
Mean E2 change- luteal index 
(n=190) 
§ 
 
 
Variables 
‡ 
 
 
Mean 
(SD) 
Age 
adjusted 
effect  
(95% 
CI) 
 
p- 
value 
Multivariate 
adjusted 
effect 
|| 
(95 % CI) 
 
p- 
value 
Age 
adjusted 
effect  
(95% 
CI) 
 
p- 
value 
Multivariate 
adjusted 
effect 
|| 
(95 % CI) 
 
p-  
value 
Age 
adjusted 
effect  
(95% 
CI) 
 
p-
value 
Multivariate 
adjusted 
effect 
|| 
(95 % CI) 
 
p- 
value 
                           
Age 
(years) 
30.7 
(3.1) 
-0.8 (-
2.0,0.4) 
0.20  -1.0 (-2.2, 
0.2) 
0.12  -0.8 (-
2.1, 0.5) 
0.22  -0.9 (-2.2, 
0.4) 
0.18  -1.3 (-
2.7, 0.1) 
0.08  -1.3 (-2.7, 
0.1) 
0.07 
Menarche 
(years) 
13.1 
(1.4) 
-0.3 (-
1.5, 1.0) 
0.67  0.1 (-1.2, 
1.4) 
0.90  -0.4 (-
1.7, 0.9) 
0.53  -0.2 (-1.5, 
1.1) 
0.75  -0.3 (-
1.7,1.1) 
0.64  0.2 (-1.3, 
1.6) 
0.83 
BMI** 
(kg/m
2) 
24.4 
(3.8) 
2.2 (1.0, 
3.4) 
0.001  2.2 (1.0, 
3.4) 
<.001  2.4 (1.2, 
3.7) 
0.0001  2.5 (1.3, 
3.8) 
<.0001  1.7 (0.4, 
3.1) 
0.01  1.7 (0.3, 
3.0) 
0.01 
WC** 
(cm) 
79.5 
(9.8) 
1.6 (0.4, 
2.8) 
0.01  1.6 (0.4, 
2.8) 
0.01  1.7 (0.4, 
2.9) 
0.01  1.7 (0.4,2.9)  <.01  1.2 (-
0.2, 2.5) 
0.09  1.1 (-0.2, 
2.5) 
0.10 
WHR**  0.77 
(0.06) 
1.4 (0.2, 
2.6) 
0.02  1.1 (-0.1, 
2.3) 
0.07  1.4 (0.2, 
2.7) 
0.03  1.3 (-
0.0,2.5) 
0.06  1.2 (-
0.1, 2.6) 
0.08  0.9 (-0.5, 
2.3) 
0.20 
DEXA** 
(%) 
34.2 
(7.6) 
1.4 (0.2, 
2.6) 
0.02  1.3 (0.1, 
2.5) 
0.04  1.4 (0.1, 
2.7) 
0.03  1.4 (0.1, 
2.7) 
0.03  1.0 (-
0.3, 2.4) 
0.14  0.8 (-
0.6,2.2) 
0.28 
                           
 
* Linear regression analyses. Regression coefficient and 95% confidence interval (CI). 
† Number may vary due to missing information 
‡ Age at entry and measurements at days 1–5 after onset of the menstrual cycle. 
§ Includes women with aligned cycles only. 
|| Adjusted for age, number of cigarettes, leisure time physical activity and birth weight. 
** BMI= Body mass index; WC= Waist circumference; WHR= Waist to hip ratio; DEXA= Total tissue fat (%)  
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Table III Estimated changes* in salivary overall average 17-ß-estradiol concentrations (pmol/L) with 95% confidence interval by 1 standard deviation (SD) increase in 
explanatory variable
‡ in groups of menarche (n =204)
† 
 
 
    Menarche  12 
(n = 49) 
 
Menarche 12-14 
(n = 100) 
Menarche  14 
(n = 55) 
 
 
p inter-
action   
 
Variables 
‡ 
 
Mean 
(SD) 
Age adjusted 
effect 
(95% CI) 
 
p- 
value 
Multivariate 
adjusted effect
|| 
(95 % CI) 
 
p-  
value 
Age adjusted 
effect 
(95% CI) 
 
p-
value 
Multivariate 
adjusted effect
|| 
(95 % CI) 
 
p-  
value 
Age adjusted 
effect 
(95% CI) 
 
p-
value 
Multivariate 
adjusted effect
|| 
(95 % CI) 
 
p- 
value 
Mean estradiol (pmol/L)    17.8  17.7  18.4   
                             
BMI** (kg/m
2)  24.4 (3.8)  3.3 (1.2, 5.3)  0.002  3.4 (1.4,5.5)  0.001  1.4 (-0.6, 3.5)  0.2  1.4 (-0.7, 3.5)  0.2  1.9 (-0.5, 4.3)  0.1  1.3 (-0.9, 3.6)  0.2  0.33 
WC ** (cm)  79.5 (9.8)  3.6 (1.7, 5.6)  <.001  3.7 (1.8, 5.7)  <.001  0.2 (-1.8, 2.1)  0.9  0.2 (-1.8,2.2)  0.8  1.1 (-1.5, 3.7)  0.4  0.6 (-1.8,3.1)  0.6  0.07 
WHR**  0.77(0.06)  4.1 (1.9, 6.3)  <.001  4.3 (2.0, 6.5)  <.001  0.4 (-1.3, 2.2)  0.7  0.3 (-1.5, 2.1)  0.7  0.4 (-2.2, 3.1)  0.7  -0.6 (-3.1,2.0)  0.7  0.03 
DEXA** (%)  34.2 (7.6)  2.8 (0.2, 5.4)  0.04  2.9 (0.2,5.5)  0.03  1.3 (-0.4, 3.0)  0.1  1.0 (-0.9,2.8)  0.3  0.7 (-1.7, 3.1)  0.6  -0.01(-2.3,2.3)  1.0  0.22 
                             
 
* Linear regression analysis. Regression coefficient and 95% confidence interval (CI) 
† Number may vary due to missing information. 
‡ Measurements at days 1–5 after onset of the menstrual cycle. 
|| Adjusted for age, number of cigarettes, leisure time physical activity and birth weight. 
** BMI= Body mass index; WC= Waist circumference; WHR= Waist to hip ratio; DEXA= Total tissue fat (%) 
 